What do systematic reviews say?

Calcineurin inhibitor (CNI) avoidance and late CNI withdrawal vs standard dose CNI

Calcineurin inhibitor (CNI) avoidance and late CNI withdrawal showed no clear difference in acute rejection: avoidance compared with standard dose CNI (low certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 2.16 [0.85, 5.49]
  3 studies · 238 participants
  Low

Calcineurin inhibitor (CNI) avoidance and late CNI withdrawal vs standard dose CNI

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 242 participants
  Very low

Calcineurin inhibitor (CNI) avoidance and late CNI withdrawal vs standard dose CNI

Calcineurin inhibitor (CNI) avoidance and late CNI withdrawal showed no clear difference in graft loss: avoidance compared with standard dose CNI (low certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.96 [0.79, 1.16]
  4 studies · 566 participants
  Low

Calcineurin inhibitor (CNI) avoidance and late withdrawal with mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Calcineurin inhibitor (CNI) avoidance and late withdrawal with… showed no clear difference in acute rejection: avoidance compared with standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 1.27 [0.98, 1.65]
  11 studies · 1844 participants
  Moderate

Calcineurin inhibitor (CNI) avoidance and late withdrawal with mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  no estimate extracted
  9 studies · 1748 participants
  Low

Calcineurin inhibitor (CNI) avoidance and late withdrawal with mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Calcineurin inhibitor (CNI) avoidance and late withdrawal with… showed no clear difference in graft loss: avoidance compared with standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 1.03 [0.72, 1.48]
  8 studies · 1420 participants
  Moderate

Low dose calcineurin inhibitors (CNI) vs standard dose CNI

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  no estimate extracted
  13 studies · 2623 participants
  Moderate

Low dose calcineurin inhibitors (CNI) vs standard dose CNI

Low dose calcineurin inhibitors (CNI) showed no clear difference in graft loss compared with to standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.75 [0.55, 1.02]
  15 studies · 3286 participants
  Moderate

Low dose calcineurin inhibitors (CNI) vs standard dose CNI

Low dose calcineurin inhibitors (CNI) showed no clear difference in adverse events: hypertension compared with to standard dose CNI (low certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.84 [0.7, 1]
  5 studies · 1877 participants
  Low

Low dose calcineurin inhibitors (CNI) vs standard dose CNI

Low dose calcineurin inhibitors (CNI) showed no clear difference in adverse events: CMV infection compared with to standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 1.23 [0.94, 1.62]
  6 studies · 1948 participants
  Moderate

Low dose calcineurin inhibitors (CNI) vs standard dose CNI

Low dose calcineurin inhibitors (CNI) showed no clear difference in adverse events: malignancy compared with to standard dose CNI (low certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.9 [0.41, 1.97]
  5 studies · 1637 participants
  Low

Low dose calcineurin inhibitors (CNI) vs standard dose CNI

Low dose calcineurin inhibitors (CNI) showed no clear difference in death compared with to standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.79 [0.5, 1.27]
  15 studies · 3462 participants
  Moderate

Low dose calcineurin inhibitors (CNI) vs standard dose CNI

Low dose calcineurin inhibitors (CNI) showed no clear difference in acute rejection compared with to standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.87 [0.76, 1]
  19 studies · 3757 participants
  Moderate

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in death compared with standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 1.16 [0.71, 1.9]
  11 studies · 2750 participants
  Moderate

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in acute rejection compared with standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 1.13 [0.91, 1.4]
  16 studies · 3300 participants
  Moderate

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  no estimate extracted
  11 studies · 1749 participants
  Moderate

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in graft loss compared with standard dose CNI (moderate certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.67 [0.45, 1.01]
  16 studies · 3304 participants
  Moderate

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in adverse events: hypertension compared with standard dose CNI (low certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.98 [0.8, 1.2]
  5 studies · 1421 participants
  Low

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in adverse events: CMV infection compared with standard dose CNI (low certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.41 [0.16, 1.06]
  5 studies · 1250 participants
  Low

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of rapamycin inhibitor (mTORi) vs standard dose CNI

Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in adverse events: malignancy compared with standard dose CNI (low certainty).

• Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 1.22 [0.42, 3.52]
  5 studies · 1074 participants
  Low